UGCG and proteostasis deficiencies: The present study supports the hypothesis that modulation of the sphingolipid pathway via inhibition of de novo GlcCer synthesis by brain-penetrant GCS inhibitors can ameliorate the proteinopathy and cognitive impairment phenotypes associated with synucleinopathies.